162 related articles for article (PubMed ID: 37740206)
1. Innovative thinking of clinical investigation for rare disease drug development.
Wang P; Chow SC
Orphanet J Rare Dis; 2023 Sep; 18(1):299. PubMed ID: 37740206
[TBL] [Abstract][Full Text] [Related]
2. Innovative design and analysis for rare disease drug development.
Chow SC; Huang Z
J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
[TBL] [Abstract][Full Text] [Related]
3. Statistical considerations for rare diseases drug development.
Chow SC; Chang YW
J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
[TBL] [Abstract][Full Text] [Related]
4. Probability monitoring procedures for sample size determination.
Huang Z; Chow SC
J Biopharm Stat; 2019; 29(5):887-896. PubMed ID: 31454274
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
7. The use of real-world data for clinical investigation of effectiveness in drug development.
Wang P; Chow SC
J Biopharm Stat; 2024 Mar; ():1-24. PubMed ID: 38519266
[TBL] [Abstract][Full Text] [Related]
8. Demonstrating effectiveness or demonstrating not ineffectiveness - A potential solution for rare disease drug product development?
Chow SC; Huang Z
J Biopharm Stat; 2019; 29(5):897-907. PubMed ID: 31454301
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease.
Spineli LM; Jenz E; Großhennig A; Koch A
Orphanet J Rare Dis; 2017 Aug; 12(1):140. PubMed ID: 28814322
[TBL] [Abstract][Full Text] [Related]
11. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.
Kidwell KM; Roychoudhury S; Wendelberger B; Scott J; Moroz T; Yin S; Majumder M; Zhong J; Huml RA; Miller V
Orphanet J Rare Dis; 2022 May; 17(1):186. PubMed ID: 35526036
[TBL] [Abstract][Full Text] [Related]
12. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.
Miller KL; Mueller C; Liu G; Miller Needleman KI; Maynard J
Orphanet J Rare Dis; 2020 Sep; 15(1):234. PubMed ID: 32883327
[TBL] [Abstract][Full Text] [Related]
13. On the use of RWD in support of regulatory submission in drug development.
Chow SC; Wang P
J Biopharm Stat; 2024 Mar; ():1-28. PubMed ID: 38501166
[TBL] [Abstract][Full Text] [Related]
14. The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology.
Merola D; Campbell U; Gautam N; Rubens A; Schneeweiss S; Wang SV; Carrigan G; Chia V; Ovbiosa OE; Pinheiro S; Bruno A; Jiao X; Stewart M; Hendricks-Sturrup R; Rodriguez-Watson C; Khosla S; Zhang Y; Rimawi M; Huang J; Taylor A; Becnel L; McRoy L; Eckert J; Taylor B
Clin Pharmacol Ther; 2023 Jun; 113(6):1217-1222. PubMed ID: 36408668
[TBL] [Abstract][Full Text] [Related]
15. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
[TBL] [Abstract][Full Text] [Related]
16. Reading the research literature. Putting randomized clinical trials into practice. 2.
Riegelman R
Md Med; 2002; 3(2):52-6. PubMed ID: 12056230
[TBL] [Abstract][Full Text] [Related]
17. Estimation of causal effect in integrating randomized clinical trial and observational data - An example application to cardiovascular outcome trial.
Zhang Y; Lin LA; Starkopf L; Chen J; Wang WWB
Contemp Clin Trials; 2021 Aug; 107():106492. PubMed ID: 34175491
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies.
Izem R; Buenconsejo J; Davi R; Luan JJ; Tracy L; Gamalo M
Ther Innov Regul Sci; 2022 Sep; 56(5):704-716. PubMed ID: 35676557
[TBL] [Abstract][Full Text] [Related]
20. A methodological framework for drug development in rare diseases. The CRESim program: Epilogue and perspectives.
Nony P; Kassai B; Cornu C;
Therapie; 2020 Apr; 75(2):149-156. PubMed ID: 32156422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
